Royalty Pharma

Royalty Pharma is a company focused on acquiring and managing revenue-generating pharmaceutical royalties.

CCI Score

50.53

-0.02% April 18

Latest Event

Royalty Pharma 2024 Political Contributions Overview

Royalty Pharma's OpenSecrets profile reports political contributions of $39,551 in the 2024 cycle, with no reported lobbying or outside spending. This limited financial engagement in politics suggests minimal corporate influence, which is viewed positively from an anti-authoritarian perspective.

Take Action

So what can you do? Support by shopping, spreading the word, or offering your support.

Shop Alternatives SEE ALL: Argenx

Verona Pharma

BMS
Use Your Voice OTHER TOOLS
Investigate
Share the Score SUPPORT CCI

LEADER

Royalty Pharma is currently rated as a Leader.

+45 to +100 CCI Score

Companies in this range actively lead the fight against authoritarianism by rejecting oppressive practices and championing democratic values. They implement robust policies, engage in transparent governance, and drive initiatives that set the standard for corporate responsibility.

Latest Events

JAN

01

2024

Royalty Pharma 2024 Political Contributions Overview
26.35

Royalty Pharma's OpenSecrets profile reports political contributions of $39,551 in the 2024 cycle, with no reported lobbying or outside spending. This limited financial engagement in politics suggests minimal corporate influence, which is viewed positively from an anti-authoritarian perspective.
+30

Political Contributions and Lobbying Efforts

March 28

The company’s reported contribution level is modest and the absence of any lobbying or outside spending indicates a restrained approach to political engagement. From an anti-fascist outlook, this minimal financial influence is commendable as it reduces potential for authoritarian influence.

Royalty Pharma Profile: Summary • OpenSecrets
JAN

01

2023

Release of 2023 Corporate Responsibility Report
63.58

Royalty Pharma published its 2023 Corporate Responsibility Report outlining its commitment to responsible business practices, sustainable growth, responsible investment, access to healthcare, talent management, environmental sustainability, and community engagement, including a notable partnership with Mount Sinai to promote health equity.
+80

Business Practices and Ethical Responsibility

March 28

The report showcases Royalty Pharma’s strong commitment to ethical and responsible business practices. Its focus on transparency, sustainable growth, and community engagement—including partnering with Mount Sinai to address health equity—indicates a progressive approach that supports worker rights and marginalized communities, aligning with anti-authoritarian values.

Royalty Pharma PLC 2023 Corporate Responsibility Report – SustainabilityReports.com
FEB

01

2022

Royalty Pharma Human Rights Policy Statement
61.65

Royalty Pharma published an updated human rights policy statement in February 2022, outlining its commitment to uphold high ethical standards, promote an inclusive and diverse workforce, and ensure fair labor practices and respect for human rights within its operations and among its business partners.
+85

Labor Relations and Human Rights Practices

March 28

The policy statement highlights Royalty Pharma's commitment to human rights by promoting non-discrimination, fair labor conditions, safe working environments, and respect for employee rights, which aligns with progressive labor practices and ethical business conduct. This proactive approach indicates a strong dedication to upholding human rights within its operations.

PDF Policy Statement on Human Rights - Royalty Pharma